By Market Intelligence Team

Clearmind Medicine Inc., a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced positive pre-clinical results for its treatment for cocaine addiction using 5-methoxy-2-aminoindane (MEAI), its novel psychedelic molecule. The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction. The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (RamatGan, Israel), was designed to evaluate possible reward-like effects of MEAI, on male Sprague-Dawley rats based on the Conditioned Place Preference (CPP) model.…